Skip to content
2000
image of Study on the Forced Degradation Behaviour of Oteseconazole and Characterization of Its Degradants by LC-MS/MS

Abstract

Introduction

Oteseconazole is a novel tetrazole antifungal agent used to treat Recurrent Vulvovaginal Candidiasis in women. Its mechanism of action is through the inhibition of cytochrome P450(CYP)51, thereby affecting the development and integrity of the fungal cell membrane. The main objective of the present work is to investigate the forced degradation behaviour of Oteseconazole, identify its degradants, and propose the fragmentation pathways of the degradants.

Methods

Good chromatographic separation of Oteseconazole was achieved using an HPLC System equipped with a PDA detector, and an X-Bridge Phenyl column (150 x 4.6mm, 5µm) with a mobile phase comprising acetonitrile and trifluoroacetic acid buffer (50:50) run in isocratic mode at 268 nm. For mass analysis, the HPLC system was connected to a SCIEX QTRAP 5500 mass spectrometer, operated in positive ion electrospray ionization interface mode.

Results

An accurate, specific, and time-efficient stability-indicating RP-HPLC method was developed for the estimation of Oteseconazole and its degradation products. The developed method was validated with Linearity in a range of 1.25µg/ mL – 7.5 µg/mL, accuracy (%RSD 0.06), system precision (%RSD 0.256), method precision (% RSD 0.49), LOD(0.3µg/mL), and LOQ(1µg/mL). Upon forced degradation studies according to ICH guidelines, Oteseconazole was found to be stable in photolytic, hydrolytic, and thermal conditions but degraded readily in acidic, alkaline, peroxide, and reduction environments.

Discussion

The developed method was robust and can be used in routine analysis to quantify Oteseconazole. The degradation behaviour of Oteseconazole was studied by performing forced degradation studies according to the ICH guidelines, and it was found to be stable in photolytic, hydrolytic, and thermal conditions, but degraded more readily in acidic, alkaline, peroxide, and reductive environments. The degradation products were characterized by LC-MS/MS, and their fragmentation pathways were proposed.

Conclusion

Oteseconazole remained stable in photolytic, hydrolytic, and thermal conditions, but showed significant degradation in acidic, alkaline, peroxide, and reductive environments. The degradation products were characterized by LC-MS/MS and characterized as 5-(4-chlorophenyl)-2-(2-(2,4-difluorophenyl)-1,1-difluoro-3-(1H-tetrazol-1-yl)propyl)pyridine (acid impurity, DP1), sodium 4-(6-(2-(2,4-difluorophenyl)-1,1-difluoro-3-(1H-tetrazol-1-yl)propyl)pyridin-3-yl)phenolate (alkali impurity, DP2), 2-(2-(2,4-difluorophenyl)-1,1-difluroropropyl)-5-(4-hydroperoxyphenyl)pyridine (peroxide impurity, DP3) and 4-(6-2(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1H-tetrazol-1-yl)propyl)pyridin-3-yl)phenyl hydrogen sulfate (reduction impurity, DP4), and their fragmentation pathways were proposed. The developed method was accurate, specific, less time-consuming, and could be used in routine analysis for the quantification of Oteseconazole.

Loading

Article metrics loading...

/content/journals/dmb/10.2174/0118723128392142250630064916
2025-07-31
2025-11-17
Loading full text...

Full text loading...

References

  1. Fung S. Shirley M. Oteseconazole in recurrent vulvovaginal candidiasis: A profile of its use. Drugs Ther. Perspect. 2023 39 8 263 269 10.1007/s40267‑023‑01008‑x
    [Google Scholar]
  2. Hoy S.M. Oteseconazole: First approval. Drugs 2022 82 9 1017 1023 10.1007/s40265‑022‑01734‑y 35713845
    [Google Scholar]
  3. De S.K. Oteseconazole: First approved orally bioavailable and selective CYP51 inhibitor for the treatment of patients with recurrent vulvovaginal candidiasis. Curr. Med. Chem. 2023 30 37 4170 4175 10.2174/0929867330666230220130024 36803759
    [Google Scholar]
  4. Jacobs S.E. Zagaliotis P. Walsh T.J. Novel antifungal agents in clinical trials. F1000 Res. 2021 10 507 10.12688/f1000research.28327.2 35136573
    [Google Scholar]
  5. Lail C.L. Hagen T.J. Oteseconazole (Vivjoa): A CYP51 inhibitor for treating recurrent vulvovaginal candidiasis. Chem. Pharmacol. Drug Discov 2024 121 10.1371/journal.ppat.1011684
    [Google Scholar]
  6. Vanreppelen G. Nysten J. Baldewijns S. Sillen M. Donders G. Van Dijck P. Oteseconazole (VIVOJA) for prevention of recurrent vulvovaginal candidiasis. Trends Pharmacol. Sci. 2023 44 1 64 65 10.1016/j.tips.2022.10.004 36396498
    [Google Scholar]
  7. Susararla K.P.C. Shelke O. Shorgar N. Quantification of oteseconazole in rat plasma using LC-MS/MS and its application to pharmacokinetic study. J. Appl. Pharm. Res. 2024 12 4 54 65 10.69857/joapr.v12i4.485
    [Google Scholar]
  8. Ravi Sankar P. Stability-indicating HPLC method development and validation for quantitative analysis of oteseconazole - A novel antifungal agent. Afr. J. Biomed. Res. 2024 27 3S 1061 1072 10.53555/AJBR.v27i3S.2218
    [Google Scholar]
  9. Murugan S. Elayaraja A. Niranjan Babu M. Chandrakala K. Prathap Naik K. Ramaiah P. A review on method development and validation by using HPLC. Int. J. Novel Trends Pharm. Sci. 2013 3 4 78 81
    [Google Scholar]
  10. Araujo P. Key aspects of analytical method validation and linearity evaluation. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2009 877 23 2224 2234 10.1016/j.jchromb.2008.09.030 18929516
    [Google Scholar]
  11. Bhardwaj S.K. Dwivedia K. Agarwala D.D. A review: HPLC method development and validation. Int. J. Anal. Bioanal Chem. 2015 5 76 81 10.5281/zenodo.14234238
    [Google Scholar]
  12. Peris-Vicente J. Chapter 13 validation of analytical methods based on chromatographic techniques: An overview. In: Analytical Separation Science; Wiley, 2015 10.1002/9783527678129.assep064
    [Google Scholar]
  13. Ravisankar P. Navya C.N. Pravallika D. Sri D.N. A review on step-by-step analytical method validation. IOSR J. Pharm. 2015 5 10 7 19
    [Google Scholar]
  14. Validation of analytical procedures: Text and methodology Q2(R1). Proceedings of Conference on Harmonization 2005 11 12
    [Google Scholar]
  15. Sahoo N.K. Sahu M. Srinivasa Rao P. Ghosh G. Validation of stability indicating RP-HPLC method for the estimation of mesalamine in bulk and tablet dosage form. Pharm. Methods 2013 4 2 56 61 10.1016/j.phme.2013.12.003
    [Google Scholar]
  16. Kumar P. Dwivedi S.C. Kushnoor A. A validated stability indicating RPHPLC method for the determination of emtricitabine in bulk and capsules. Farmacia 2012 60 3 402 410
    [Google Scholar]
  17. Singh S. Junwal M. Modhe G. Tiwari H. Kurmi M. Parashar N. Sidduri P. Forced degradation studies to assess the stability of drugs and products. Trends Analyt. Chem. 2013 49 71 88 10.1016/j.trac.2013.05.006
    [Google Scholar]
  18. Kogawa C. Impurities and forced degradation studies: A review. Curr. Pharm. Anal. 2016 12 18 24 10.2174/1573412911666150519000155
    [Google Scholar]
  19. Sharma M.K. Murugesan M. Forced degradation study an essential approach to develop stability indicating method. J. Chromatogr. Sep. Tech. 2017 8 1 349 10.4172/2157‑7064.1000349
    [Google Scholar]
  20. Jain D. Basniwal P.K. Forced degradation and impurity profiling: Recent trends in analytical perspectives. J. Pharm. Biomed. Anal. 2013 86 11 35 10.1016/j.jpba.2013.07.013 23969330
    [Google Scholar]
  21. Iram F. Iram H. Iqbal A.Z. Husain A. Forced degradation studies. J. Anal. Pharm. Res. 2016 3 73
    [Google Scholar]
  22. Venkataraman S. Manasa M. Forced degradation studies: Regulatory guidance, characterization of drugs, and their degradation products-a review. Drug Invent. Today 2018 10 2
    [Google Scholar]
  23. Himmelsbach M. 10years of MS instrumental developments – Impact on LC–MS/MS in clinical chemistry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2012 883-884 3 17 10.1016/j.jchromb.2011.11.038 22177236
    [Google Scholar]
  24. Ermer J. Vogel M. Applications of hyphenated LC-MS techniques in pharmaceutical analysis. Biomed. Chromatogr. 2000 14 6 373 383 10.1002/1099‑0801(200010)14:6<373:AID‑BMC29>3.0.CO;2‑S 11002275
    [Google Scholar]
  25. Guo K. He X. Zhao H. Ma C. Characterisation of degradation products of tegoprazan by LC-MS and GC-MS. J. Pharm. Biomed. Anal. 2023 228 115323 10.1016/j.jpba.2023.115323
    [Google Scholar]
/content/journals/dmb/10.2174/0118723128392142250630064916
Loading
/content/journals/dmb/10.2174/0118723128392142250630064916
Loading

Data & Media loading...


  • Article Type:
    Research Article
Keywords: degradation ; validation ; ICH ; RP-HPLC ; isocratic ; Oteseconazole ; LC-MS/MS
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test